OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
U.S. Dollar Steadies Ahead of Fed Minutes as Markets Eye Policy Divisions 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Asian Markets Slip as Precious Metals Cool, Geopolitical Tensions Weigh on Sentiment 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Citi Forecasts a Volatile but Ongoing Bull Market for S&P 500 in 2026 
South Korean Won Slides Despite Government Efforts to Stabilize Currency Markets 
U.S. Stocks Slip as Gold Rebounds Ahead of Year-End, Markets Eye 2026 Outlook 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Wall Street Ends Mixed as Tech and Financial Stocks Weigh on Markets Amid Thin Holiday Trading 
Federal Reserve Begins Treasury Bill Purchases to Stabilize Reserves and Money Markets 
Asian Markets End Year on AI Optimism as Precious Metals and Currencies Shine 
Samsung Biologics is investing $5.3 billion to build new facilities that will allow it to double its contract development and manufacturing organization or CDMO capacity. It will construct its second Biocampus, and it has already signed a deal with Incheon for this expansion project.
As per The Korea Herald, Samsung Biologics is expanding its facilities so it can bolster its capabilities to develop new therapeutics. For this, the company inked a land sale contract with the Incheon metropolitan city for the acquisition of space for its new plants. The company said that the sales contract is worth KRW426 billion or around $323 million.
It was mentioned that the agreement mainly centers on the construction of Samsung Biologics' research and manufacturing planta in the 11th district of Songdo International City, a location that is inside the Incheon Free Economic Zone (IFEZ).
The land which the company bought is said to measure 357,000 square meters, and it is 30% bigger compared to its first Biocampus, which only sits on 238,000 square meters of land in Songdo.
Samsung Biologics is building four plants in its Biocampus 2, and this may cost the company some KRW7 trillion. Currently, it is running three factories, and a fourth facility is being built on the first campus.
The CDMO firm decided to double its manufacturing and development capacity so it could respond to the high demands in the global biopharmaceutical business sector. The demand rose amid the series of pandemic outbreaks.
"This milestone further solidifies our roadmap to build a world-class global bio-hub at the heart of Songdo," Samsung Biologics president and chief executive officer, John Rim, said in a press release. "Through continuous investment, we will maintain our position as the best-in-class CDMO partner, fully equipped with the world's largest manufacturing capacity and provide diverse service offerings to our clients to address new emerging diseases and save lives of patients worldwide."
Finally, the land where Samsung Biologics' second Biocampus is set to be built was awarded to the company in conformity with IFEZ's strategy to boost the region's global competitiveness in the biopharma business while also encouraging partnerships with small and mid-sized firms. The new facilities are also expected to create 4,000 new jobs in the area by 2032.
"Samsung Biologics' achievements over the past decade are remarkable and highly impressive," Incheon's Mayor Jeong Bok Yoo commented on the project. "The city will do its best to support the development of the bio industry's infrastructure and further drive Songdo to become a global bio hub."
